A Loss Of Goodwill: Why It May Be Best To Avoid These 2 Healthcare Stocks
When it comes to acquisitions, “goodwill”, as the author of today’s article explains, “represents the premium an acquiring company paid over an acquisition target’s net…
stocks
A “Treasure Hunt” Options Play As Retail Reopens
As the retail business highlighted in today’s article has reopened, “Customers have been braving public spaces in droves to visit its brick-and-mortar locations and tear…
Bored Retail Traders’ Journey Into “All Manner Of Wall Street Exotica” – And Why It’ll End Badly
Bored from staying at home, and lured by free trading, individual investors are engaging in some new – and perhaps ill-advised – activities in the…
3 “Compelling, But Affordable” Biotech Names For A Bullish View Of The Market
In a bullish take on current circumstances, Morgan Stanley’s head of U.S. equity strategy argued in a recent note to clients that the current state…
Upside Potential In The Pipelines: 3 “Strong Buy” Biotech Stocks To Consider
Some sectors are holding up much better than others in the current market environment – and offering compelling plays in the process. One of those…
More Evidence That Biotech Is The “Next Gold Mine”
If you need any further evidence of just how much the COVID-19 pandemic has increased the allure of biotechnology stocks, consider the little-known Chinese biotech…
Are These Biotech And Energy Stocks The Best Penny Stock Picks Right Now?
In the world of penny stocks, biotech penny stocks and energy penny stocks have been among the big movers recently – and the author of…
What Are Insiders Seeing In This Clinical-Stage Biotech?
The clinical-stage biopharmaceutical company highlighted in today’s article is focused on the development of novel therapies for cardio-metabolic disease, liver disease, ophthalmic disease and cancer…
“Imminent Danger”: These 4 Energy Stocks Could Be Kicked Out Of The S&P 500
Thanks to it ensuring a ready supply of buyers, buying stocks that are about to be included in the S&P 500 has proven to be…
Don’t Overlook This Cancer Biotech In The Age Of Coronavirus
This clinical-stage biopharmaceutical company focused on developing treatments for different kinds of cancers just recently launched an IPO, making it just the second IPO to…